Want to see JP:7747 full AI Analyst Report?
Top Page
Asahi Intecc Co
(7747)
Select Model
Select Model
Rating:78Outperform
Price Target:
¥3,834.00
▼(-2.29% Downside)
Action:Reiterated
Date:08/19/26
The score is driven primarily by strong financial performance (improving profitability, steady growth, and low leverage). Technicals are supportive with clear trend strength, though momentum indicators suggest the stock may be stretched short-term. Valuation is the main constraint due to a high P/E relative to the modest dividend yield.
Positive Factors
Steady Revenue Growth
Sustained revenue growth indicates expanding demand for the company’s medical devices and components across its served markets. Continued top-line expansion can support operating leverage, strengthen customer relationships, and provide a durable base for reinvestment in minimally invasive treatment technologies.
Negative Factors
Variable Free Cash Flow
Although recent operating cash generation is solid, the historical inconsistency of free cash flow makes the company’s ability to convert accounting earnings into reusable cash less predictable. Working-capital needs or reinvestment can therefore constrain capital returns and self-funded expansion in weaker periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue growth indicates expanding demand for the company’s medical devices and components across its served markets. Continued top-line expansion can support operating leverage, strengthen customer relationships, and provide a durable base for reinvestment in minimally invasive treatment technologies.
Read all positive factors
Asahi Intecc Co (7747) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥892.29B
Dividend Yield1.43%
Average Volume (3M)1.30M
Price to Earnings (P/E)28.5
Beta (1Y)0.65
Revenue Growth21.16%
EPS Growth156.97%
CountryJP
Employees10,177
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)114.80
Shares Outstanding265,332,300
10 Day Avg. Volume1,419,400
30 Day Avg. Volume1,303,600
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.83
Price to Sales (P/S)6.95
P/FCF Ratio31.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)143.75
Revenue Forecast (FY)¥162.84B
Asahi Intecc Co Business Overview & Revenue Model
Company Description
Asahi Intecc Co., Ltd. is a global enterprise dedicated to the research, manufacturing, and distribution of advanced medical devices. Its market reach extends across Japan, the United States, Europe, the Middle East, and China, with a significant ...
How the Company Makes Money
Asahi Intecc primarily makes money by manufacturing and selling medical devices and related components used in minimally invasive procedures. A major revenue stream comes from the sale of proprietary guidewires and catheter/vascular-intervention a...
Asahi Intecc Co Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 136.58B | 145.42B | 120.03B | 107.55B | 90.10B | 77.75B |
| Gross Profit | 95.76B | 99.39B | 78.23B | 66.11B | 56.26B | 49.24B |
| EBITDA | 50.42B | 53.98B | 29.01B | 31.73B | 26.76B | 23.34B |
| Net Income | 30.63B | 32.08B | 12.74B | 15.81B | 13.11B | 10.86B |
Balance Sheet | ||||||
| Total Assets | 203.73B | 218.28B | 193.19B | 191.61B | 172.64B | 155.13B |
| Cash, Cash Equivalents and Short-Term Investments | 59.80B | 64.26B | 54.20B | 38.66B | 36.88B | 32.32B |
| Total Debt | 7.23B | 8.66B | 11.52B | 8.20B | 15.87B | 13.22B |
| Total Liabilities | 36.57B | 43.92B | 41.83B | 39.65B | 38.34B | 33.99B |
| Stockholders Equity | 166.23B | 173.41B | 150.56B | 151.22B | 132.31B | 119.46B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 31.71B | 32.45B | 24.83B | 6.85B | 9.32B |
| Operating Cash Flow | 0.00 | 40.09B | 40.54B | 34.71B | 19.14B | 17.30B |
| Investing Cash Flow | 0.00 | -11.74B | -13.43B | -21.22B | -15.13B | -18.70B |
| Financing Cash Flow | 0.00 | -19.97B | -8.11B | -13.88B | -2.34B | 11.37B |
Asahi Intecc Co Technical Analysis
Negative
3924.00
Price Trends
3591.76
Negative
3600.58
Negative
3334.06
Positive
Market Momentum
-49.62
Negative
45.33
Neutral
62.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7747, the sentiment is Negative. The current price of 3924 is above the 20-day moving average (MA) of 3316.00, above the 50-day MA of 3591.76, and above the 200-day MA of 3334.06, indicating a neutral trend. The MACD of -49.62 indicates Negative momentum. The RSI at 45.33 is Neutral, neither overbought nor oversold. The STOCH value of 62.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7747.
Asahi Intecc Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | ¥146.99B | 21.86 | ― | 2.75% | 9.94% | 10.50% | |
80 Outperform | ¥3.37T | 20.77 | 10.60% | 1.44% | 14.05% | 31.94% | |
78 Outperform | ¥892.29B | 28.49 | 19.88% | 1.43% | 21.16% | 156.97% | |
70 Outperform | ¥2.20T | 28.64 | 10.21% | 3.00% | 7.80% | -27.73% | |
60 Neutral | ¥253.11B | 105.32 | 1.89% | 2.02% | 14.87% | -55.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥215.12B | 15.41 | 5.35% | 2.35% | 2.68% | 144.20% |
* Healthcare Sector Average
JP:7747
Asahi Intecc Co
3,363.00
1,088.84
47.88%
JP:4543
Terumo
2,284.00
-138.01
-5.70%
JP:7716
Nakanishi
1,433.00
428.39
42.64%
JP:8086
Nipro
1,319.00
-127.54
-8.82%
JP:7733
Olympus
2,000.00
248.95
14.22%
JP:7730
Mani, Inc.
1,492.00
90.86
6.48%
Asahi Intecc Co Corporate Events
Asahi Intecc Reports FY2026 Results and Issues FY2027 Outlook
Aug 14, 2026
Asahi Intecc Co. released its consolidated financial results for the fiscal year ended June 2026, providing investors with an overview of recent performance and profitability. The disclosure serves as a basis for assessing the company’s curr...
Asahi Intecc Delivers Record Earnings and Doubles Dividend on Strong FY2026 Performance
Aug 14, 2026
Asahi Intecc Co., Ltd. is a Japanese medical device maker listed in Tokyo and Nagoya, known for its advanced catheter and guide wire products used in minimally invasive cardiovascular treatments worldwide. The company targets high-growth intervent...
Asahi Intecc Doubles Dividend as It Tightens 35% Payout Policy
Aug 14, 2026
Asahi Intecc Co., Ltd. said its board has approved a proposal to distribute a year‑end dividend for the fiscal year ended June 30, 2026, with a dividend of 48.24 yen per share and a total payout of 5,533 million yen, sourced from retained ea...
Asahi Intecc Secures Japan Exclusivity for Nuvascular Aneurysm Device
Aug 14, 2026
Asahi Intecc has signed an exclusive distribution agreement with California‑based Nuvascular, Inc. to sell its intrasaccular occlusion device, HARBOR, in Japan once regulatory approval is obtained. The device, currently in clinical trials fo...
Asahi Intecc Updates 2030 Plan to Drive Sustainable Global Growth
Aug 14, 2026
Asahi Intecc has outlined an updated medium-term management plan, titled “Building the Future 2030 ~Unlocking Sustainable Growth~,” signaling a strategic push to refine its numerical targets and strengthen its long-term growth trajecto...
Asahi Intecc Raises 2030 Plan and Long-Term Profit Targets on Strong Performance
Aug 14, 2026
Asahi Intecc has revised upward the financial targets in its medium-term management plan, Building the Future 2030, after outperforming initial assumptions on sales growth and profitability. Strong market share gains across regions, productivity i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.